Identification of a New Gene Involved in Hereditary Lipodystrophy

Lipodystrophy Clinical Trial

— LIPOGENE  

Official title:

Identification of a New Gene Involved in Hereditary Lipodystrophy - LIPOGENE

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02056912
• Other study ID #: CHUBX 2013/13
• Status: Completed
• Phase: N/A
• First received: January 24, 2014
• Last updated: January 13, 2015
• Start date: January 2014
• Est. completion date: January 2014

Study information

• Verified date: January 2015
• Source: University Hospital, Bordeaux
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of HealthFrance: ANSM
• Study type: Interventional

Clinical Trial Summary

Human lipodystrophies (lipoD) represent a heterogeneous group of diseases characterized by generalized or partial fat loss, with fat hypertrophy in other depots when partial.3, 4 Insulin resistance, dyslipidemia and diabetes are generally associated, leading to early complications. Acquired lipoD can be generalized, resembling congenital forms, or partial, as the Barraquer-Simons syndrome, with loss of fat in the upper part of the body contrasting with accumulation in the lower part. The most common forms of lipoD are iatrogenic. In human immunodeficiency virus-infected patients, some first-generation antiretroviral drugs were strongly related with peripheral lipoatrophy and metabolic alterations. Genetic forms are very uncommon: recessive generalized congenital lipoD result in most cases from mutations in the genes encoding seipin or the 1-acyl-glycerol-3-phosphate-acyltransferase 2 (AGPAT2). Dominant partial familial lipoD result from mutations in genes encoding the nuclear protein lamin A/C or the adipose transcription factor PPARgamma. Importantly, LMNA mutations are also responsible for metabolic laminopathies, resembling the metabolic syndrome and progeria, a syndrome of premature aging. Molecular genetic bases of many rare forms of genetic lipoD remain to be elucidated.

Description:

The investigators have recently evaluated two sisters (index patients) affected by a syndrome associating diffuse leukoencephalopathy and partial lipoD. The investigators have analyzed numerous known genetic causes of leukodystrophies and lipoD but the investigators failed to identify a known cause for this syndrome which has never been previously reported. The investigators then switched their effort to analyses of exome using next generation sequencing in both affected sisters and their unaffected relatives (one sister and two parents). The investigators identified an excellent candidate gene with a homozygous missense mutation in both affected sisters. The investigators now aim to prove the involvement of this candidate gene in lipoD's determinism by a search of additional mutations in the candidate gene in a series of patients affected with lipoD (collaboration with Pr Capeau's Team) (LIPOGENE study) and by functional analyses performed in the two index patients on blood and skin samples (LIPOGENE sub-study).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: January 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Study :

• Patients affected by lipoD

• No identified genetic cause of lipoD

• Child or adult

• DNA already available in the French reference laboratory for the genetic diagnosis of lipoD (laboratoire de Biochimie du CHU Saint-Antoine, Paris) or in the INSERM UMRS 938 laboratory, Faculté de médecine Pierre et Marie Curie Site Saint-Antoine, Paris

• Subject affiliated to the french Sécurité Sociale

• Signed consent obtained for the molecular diagnosis of lipoD.

Sub-study:

• Signed consent obtained for this sub-study from both index patients

Exclusion Criteria:

Study:

• Identified genetic cause of lipoD

• No signed consent by the patient

• Subject not affiliated to the french Sécurité Sociale.

Sub-study:

• Absence of signed consent obtained for this sub-study from both index patients

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Lipodystrophy

Intervention

Genetic:
• Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene

Biological:
• Perform blood cells and fibroblasts biochemical and immuno-labeled investigations
Performed only in the two index patients enrolled in the sub-study

Locations

Country	Name	City	State
France	Service de Génétique Médicale	Bordeaux

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Additional mutation in the studied candidate gene XX	Study's primary outcome	6 months	No
Primary	Altered lipids composition in blood red cells membranes	Sub-study's primary outcome	6 months	No
Primary	Quantitative or qualitative variation of the protein encoded by the candidate gene in fibroblasts	Sub-study's primary outcome	6 months	No
Primary	Dense deposits in fibroblasts cytoplasm	Sub-study's primary outcome	6 months	No
Primary	Phospholipids anomalies in plasma	Sub-study's primary outcome	6 months	No